Study of a new drug for fatty liver in type 2 diabetes
Part of Digestive system, Hormones & metabolism clinical trials.
This trial tests an investigational drug (called Henggliejin) to see if it can improve fatty liver in people who also have type 2 diabetes. If you have both conditions and your blood sugar is not well controlled on your current diabetes pills, this study might be a good fit.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have type 2 diabetes confirmed by a doctor.
- You have been diagnosed with non-alcoholic fatty liver disease (a buildup of fat in the liver not caused by alcohol).
- Your most recent HbA1c (a blood test for average blood sugar) is between 7% and 10%.
- You have a body mass index (BMI) of 24 or higher.
- You are currently taking diabetes medication (but not certain types like insulin, TZDs, SGLT2 inhibitors, GLP-1 agonists, or GKAs) and have been on a stable dose for at least 8 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a medicine called henagliflozin can help reduce fat in the liver for people with type 2 diabetes and non-alcoholic fatty liver disease. It may help improve liver health and blood sugar control at the same time.
This trial tests a diabetes drug called empagliflozin to see if it can reduce fat and inflammation in the liver in people with a specific type of fatty liver disease called NASH. It may help if you have NASH and either have type 2 diabetes or don't have it.
This trial studies whether erugliflozin can reduce liver fat and liver scarring (fibrosis) while also improving blood sugar in people with type 2 diabetes and fatty liver disease (NASH/NAFLD). It’s designed for people who haven’t used certain diabetes medicines like SGLT2 inhibitors or insulin before.
This Phase 2 study tests whether low-dose pioglitazone can improve NASH, a type of fatty liver disease, in adults who also have type 2 diabetes. You may be able to join if your diabetes medicines and lab tests meet specific safety and stability requirements.
This study tests how safe and effective the diabetes medication henagliflozin is for Chinese patients with type 2 diabetes. It is an observational study, meaning you will continue your regular care while researchers watch your progress.
This trial tests a new oral medication, Chiglitazar, for people who have both type 2 diabetes and a fatty liver condition called MASH (fatty liver with inflammation and scarring). It aims to see if the drug can help improve liver health and diabetes control.
Hear when a new NAFLD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.